drugset / Trial / NCT02521714

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

NCT02521714 ↗

Phase 1 Completed 28 enrolled Celgene Corporation
RandomizedCrossoverOpen-labelOther

Summary

This study will evaluate the amount of drug that reaches the circulation when a subject takes the test (liquid) formulation compared to the reference (capsule) formulation. The study will also examine the effect of a high fat meal on the levels of drug in blood.

Timeline

Start
2015-08-14
Primary completion
2015-09-23
Completion
2015-09-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified 25 mg Oral

Indications

No indication recorded.